Double&amp;ndash;Blind Trial of the Efficacy and Tolerability of Doxazosin in the Gastrointestinal Therapeutic System, Doxazosin Standard, and Placebo in Patients with Benign Prostatic Hyperplasia

Dahlstrand, Christer; Høye, Kjetil

doi:10.1159/000020315

Cited by 51 publications

(70 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, the controlled-release gastrointestinal therapeutic system (GITS) formulation of doxazosin (Cardura XL) enhances the drug delivery rate and minimises the need for titration. 8 Doxazosin GITS significantly improves LUTS with no adverse effect on sexual function and appears to be better tolerated than the standard formulation. 8 Tamsulosin is an alpha 1A and alpha 1D selective antagonist whose efficacy and tolerability have been established in a number of short-term randomised, placebo-controlled trials in both Europe and the USA.…”

Section: Alpha-blockersmentioning

confidence: 97%

“…8 Doxazosin GITS significantly improves LUTS with no adverse effect on sexual function and appears to be better tolerated than the standard formulation. 8 Tamsulosin is an alpha 1A and alpha 1D selective antagonist whose efficacy and tolerability have been established in a number of short-term randomised, placebo-controlled trials in both Europe and the USA. In all trials, tamsulosin was well tolerated and associated with significant improvements in symptoms and urinar y peak flow rate compared to placebo.…”

Section: Alpha-blockersmentioning

confidence: 97%

See 1 more Smart Citation

Recommended drug treatment of BPH in primary care

Taylor¹,

Foley²,

Kirby³

2008

Prescriber

View full text Add to dashboard Cite

The development of safe and effective drugs for the treatment of BPH has allowed many patients to be managed in primary care. Our Drug review considers the efficacy and sideeffects of current treatments, followed by sources of further information and an analysis of prescription data. Development of safe and effective medical therapies and evidence-based prescribing has meant the role of GPs in BPH treatment has become increasingly important. As a result the British Association of Urological Surgeons (BAUS) has revised guidelines originally devised in 1997 to make them more applicable to the primary care setting (see Figure 1). 3 Presentation and evaluation of the patientCurrently, patients will generally consult their GP only when their LUTS are sufficiently bothersome to

show abstract

Section: Alpha-blockersmentioning

confidence: 97%

Section: Alpha-blockersmentioning

confidence: 97%

Recommended drug treatment of BPH in primary care

Taylor¹,

Foley²,

Kirby³

2008

Prescriber

View full text Add to dashboard Cite

show abstract

“…In trials of doxazosin GITS and doxazosin standard in patients with BPH, 21,22 both formulations were shown to significantly improve the symptoms of BPH, as shown by a 45% reduction for each in total IPSS from baseline to final visit, compared with a 34% reduction in patients taking placebo. Doxazosin GITS and doxazosin standard produced comparable improvements in Q max that were significantly greater than with placebo, with a greater improvement sooner after treatment with doxazosin GITS than with doxazosin standard.…”

Section: Doxazosin Gits In Bphmentioning

confidence: 98%

“…Doxazosin GITS is as effective as standard doxazosin in the treatment of hypertension [16][17][18][19][20] or BPH. 18,[21][22][23] Although the blood pressure-lowering effect of doxazosin is a therapeutic advantage in patients with comorbid BPH and hypertension, it has been erroneously perceived as less desirable in normotensive men. However, the degree of blood pressure lowering with doxazosin differs markedly in hypertensive and normotensive patients.…”

Section: Introductionmentioning

confidence: 99%

Clinical ease of using doxazosin in BPH patients with and without hypertension

Steers

Kirby

2005

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Clinical studies have demonstrated that doxazosin therapy reduced blood pressure (BP) in patients with benign prostatic hyperplasia (BPH) who were hypertensive at baseline but not in patients who were physiologically or pharmacologically normotensive at baseline. In patients with BPH and uncontrolled hypertension, despite treatment with other antihypertensive drugs, the addition of doxazosin resulted in improved control with significant reductions in BP. The new formulation, doxazosin gastrointestinal therapeutic system (GITS), is initiated at a therapeutic dose, simplifying dose titration. Based on its efficacy and pharmacokinetic and tolerability profiles, doxazosin GITS is an effective and welltolerated treatment for normotensive and hypertensive patients with BPH. Prostate Cancer and Prostatic Diseases (2005) 8, 152-157.

show abstract

“…Mit den empfohlenen Dosierungen von 7,5-10 mg/Tag können Symptome im Mittel um 30-40% gelindert und Q max um knapp 2 ml/s verbessert werden. Die GITS-Formulierung von Doxazosin wurde in einer Studie randomisiert doppelblind mit der Standardformulierung [10] und in einer weiteren sowohl mit der Standardformulierung als auch mit Placebo verglichen [11]. Die Ergebnisse beider Studien wurden in einer Metaanalyse zusammengefasst [12].…”

Section: Alfuzosinunclassified

α1-Rezeptorenblockade zur Therapie des BPH-Syndroms Richtige Dosierung für optimale Wirkung

Berges

Michel²,

Jonas

2002

Urologe [A]

View full text Add to dashboard Cite

Four alpha 1-adrenoceptor antagonists are currently available for the medical treatment of lower urinary tract symptoms suggestive of benign prostatic obstruction in Germany: alfuzosin, doxazosin, tamsulosin, and terazosin. Indirect comparison based on randomized, placebo-controlled trials as well as several direct comparative studies have shown equal efficacy of all four drugs on urinary flow and symptom relief if suggested dosing regimens are applied. A dosing regimen below this recommendation should be restricted to those patients who have a proven satisfactory response to a lower dose.

show abstract

Double–Blind Trial of the Efficacy and Tolerability of Doxazosin in the Gastrointestinal Therapeutic System, Doxazosin Standard, and Placebo in Patients with Benign Prostatic Hyperplasia

Cited by 51 publications

References 16 publications

Recommended drug treatment of BPH in primary care

Recommended drug treatment of BPH in primary care

Clinical ease of using doxazosin in BPH patients with and without hypertension

α1-Rezeptorenblockade zur Therapie des BPH-Syndroms Richtige Dosierung für optimale Wirkung

Contact Info

Product

Resources

About